Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + R-CHOP in DLBCL and High Grade B-NHL
NCT03704714Phase 2Suspended
- Sponsor
- Northwestern University
- Start
- Nov 2018
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in diffuse large B-cell lymphoma (DLBCL), Transformed Follicular Lymphoma (tFL) and high grade B-cell lymphoma (HGBCL), sponsored by Northwestern University. Primary endpoints: Maximum Tolerated Dose at 18 months and Progression-Free Survival at 18 months. Started Nov 2018; status: suspended.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Transformed Follicular Lymphoma (tFL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT03704714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704714.